According to BM-blast counts, a trend for FOXM1 downregulation was observed in MDS versus AML samples, both de novo and therapy-related (p = 0.0552 and p = 0.0593, respectively, data not shown). This evidence concerns the gene FOXM1 and myelodysplastic syndrome.